GEN Exclusives

More »

GEN News Highlights

More »
May 15, 2007

Anaptys Biosciences Acquires IP for Antibody Discovery and Protein Optimization

  • Anaptys Biosciences obtained exclusive licenses to complementary somatic hypermutation technologies from the UK Medical Research Council (MRC) and the Albert Einstein College of Medicine of Yeshiva University (AECOM). Somatic hypermutation is the natural process our bodies use for generating antibody diversity to fight disease.

    Anaptys says its Omnitope-SHM™ System utilizes the key components of somatic hypermutation to enable the rapid variation and functional selection of evolved proteins with enhanced bioactivities.

    "The MRC and AECOM technologies augment Anaptys' in-house development of proprietary vectors and methods for creating antibodies and other proteins," says William Boyle, Ph.D., co-founder, president and CSO of Anaptys. "With our Omnitope-SHM System, we can tap into the sequence variations brought about by SHM to rapidly and efficiently discover and optimize antibodies for a diverse set of disease targets."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?